PTG007
Type 1 Diabetes (newly diagnosed)
Key Facts
About PolTREG
PolTREG is a clinical-stage biotech leveraging over 17 years of foundational research to develop Treg-based therapies for autoimmune diseases, with the goal of restoring immune tolerance. Its lead asset, PTG007, is in clinical trials for Type 1 Diabetes and Multiple Sclerosis, and the company is building a next-generation pipeline of engineered CAR-Tregs. Strategically, PolTREG aims to become a global leader in the field, supported by its proprietary manufacturing capabilities and a clear path to seek partnerships with major pharmaceutical companies for commercialization.
View full company profileAbout PolTREG
PolTREG is a clinical-stage biotech leveraging over 17 years of foundational research to develop Treg-based therapies for autoimmune diseases, with the goal of restoring immune tolerance. Its lead asset, PTG007, is in clinical trials for Type 1 Diabetes and Multiple Sclerosis, and the company is building a next-generation pipeline of engineered CAR-Tregs. Strategically, PolTREG aims to become a global leader in the field, supported by its proprietary manufacturing capabilities and a clear path to seek partnerships with major pharmaceutical companies for commercialization.
View full company profile